Glenmark Pharmaceuticals has decided to take full control of the commercialisation and distribution of its allergy nasal spray Ryaltris in the US, moving away from the local partnership model it has followed since the product’s launch in 2022.
Until now, Ryaltris has been marketed in the American market by Glenmark’s distribution partner, Hikma Pharma. The company said the change will allow it to work more closely with healthcare providers and respond faster to market needs.
Marc Kikuchi, President and Business Head, North America, Glenmark, said the move gives the company greater operational direction in how it engages the market and supports healthcare providers and patients across the nation.
Glenmark said it expects the shift to strengthen margins as it will retain revenue that was earlier shared with its partner. The company has built a strong commercial footprint in the US, which it believes will support the direct-marketing strategy.
Ryaltris is a fixed-dose combination of olopatadine hydrochloride, an antihistamine, and mometasone furoate, a corticosteroid, and is approved for treating symptoms associated with seasonal allergic rhinitis.
The brand is currently marketed in 55 countries, including the US, EU and Australia. It was also recently launched in China after receiving marketing approval from the National Medical Products Administration in November 2025.
